PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8434212

[Essential cryoglobulinemia].

A Pechère-Bertschi·J A Schifferli
View original source ↗Export metadata ↓

Abstract

The diagnosis of cryoglobulinemia relies on an in vitro artefact, i.e. the precipitation of immunoglobulins induced by a drop in temperature. Cryoglobulinemia has been described in association with neoplasia, infectious and connective tissue diseases. They are classified into two major groups: monoclonal or mixed (more than one type of immunoglobulin). In many patients the mixed type has been described as essential because of the absence of an associated disease. Recent evidence suggests, though, that more than half and probably up to 90% of mixed 'essential' cryoglobulinemias are in fact associated with chronic liver disease due to hepatitis C virus infection. This observation would be in accordance with the clinical response of half of these patients to interferon-alpha therapy; however, more prospective studies are required to confirm the possible beneficial effect of interferon alpha.

Explore related subjects

Adrenal Cortex HormonesCombined Modality TherapyCryoglobulinemiaGlomerulonephritisHepatitis CHepatitis, ChronicHumansInterferon-alphaPlasmapheresisEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Pechère-Bertschi, J A Schifferli. 1993-02-09. [Essential cryoglobulinemia].. https://pubmed.ncbi.nlm.nih.gov/8434212/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗
PubMed2007

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗